GNRHR2P1

Across TCGA pan-cancer cohorts, GNRHR2P1 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of GNRHR2P1’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where GNRHR2P1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GNRHR2P1 is over-expressed in tumor, although a few such as PAAD and STAD show the opposite, repressed pattern.

BLCA, PAAD, and STAD are the cancer types where GNRHR2P1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GNRHR2P1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Female	IV	+0.170	.002	2	view →
PAAD	Female	All	−0.155	.047	2	view →
STAD	All	IV	−0.130	.019	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

GNRHR2P1–BLCA

Open the BLCA breakdown →